Rigel Pharmaceuticals Inc (RIGL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $823.43M
Last updated: Nov 17, 2026 at 4:15 PM ET
Rigel Pharmaceuticals Inc (RIGL) Statistics
Rigel Pharmaceuticals (RIGL) has a market cap of $823.43M and an enterprise value of $784.02M. It kept 106.59% of revenue as net income over the last 12 months. Its share count is up 3.73% from a year earlier.
Total Valuation
Enterprise value is 4.79% below the market cap, as cash exceeds debt.
| Market Cap | $823.43M |
|---|---|
| Enterprise Value | $784.02M |
| Latest price (Nov 17, 2026) | $42.92 |
Key Dates
The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.8x and 1.8x. Its year-end P/E ranged from 6.6x to 378.6x from 2021 to 2025.
| P/E Ratio | 13.9x |
|---|---|
| Forward P/E | 14.5x |
| P/S Ratio | 2.8x |
| Forward P/S | 2.7x |
| P/B Ratio | 1.8x |
| P/TBV Ratio | 2.3x |
| P/OCF Ratio | 9.2x |
Enterprise Valuation
Counting debt and cash, the company is valued at 9.7x EBITDA.
| EV / Earnings | 2.6x |
|---|---|
| EV / Sales | 2.7x |
| EV / EBITDA | 9.7x |
| EV / EBIT | 10.4x |
Price Statistics
The stock is up 2.34% over 52 weeks and trades 9.16% below its 50-day average.
| Beta (1Y) | 1.08 |
|---|---|
| 52-Week Change | +2.34% |
| 1-Month Change | -8.13% |
| 3-Month Change | -8.60% |
| 6-Month Change | +51.66% |
| 5-Year Change | +52.71% |
| 10-Year Change | +97.35% |
| Total Return (1Y) | +2.34% |
| Total Return (3Y CAGR) | +68.43% |
| Total Return (5Y CAGR) | +7.79% |
| Return vs SPY (1Y) | -18.70% |
| Max Drawdown (1Y) | -50.08% |
| Max Drawdown (3Y) | -50.76% |
| Sharpe Ratio (1Y) | -0.14 |
| Correlation with SPY (1Y) | 0.27 |
| 50-Day Average | $47.25 |
| 200-Day Average | $37.66 |
| 52-Week Range | $24.95 to $52.60 |
| RSI (14 Days) | 40.9 |
| Average Volume (20 Days) | 247.41K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.39x current liabilities, and total debt is 0.02x shareholder equity.
| Current Ratio | 2.39x |
|---|---|
| Quick Ratio | 2.19x |
| Debt / Equity | 0.02x |
| Debt / EBITDA | 0.09x |
| Interest Coverage | 18.17x |
Returns and Efficiency
Return on invested capital is 16.74% over the last 12 months, against a 5-year average of -39.33%.
| Return on Equity (ROE) | 69.02% |
|---|---|
| Return on Assets (ROA) | 58.64% |
| Return on Invested Capital (ROIC) | 16.74% |
| Return on Capital Employed (ROCE) | 17.02% |
| ROA (5Y Average) | 1.28% |
| ROIC (5Y Average) | -39.33% |
| Asset Turnover | 0.75x |
| Inventory Turnover | 1.98x |
| Receivables Turnover | 5.12x |
| Cash Conversion Cycle | 161 days |
Scores
RIGL has an Altman Z-Score of 4.77, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 4.77 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $288.21M over the last 12 months is up 2.18% from the 12 months before.
| Revenue | $288.21M |
|---|---|
| Revenue Growth (YoY) | +2.18% |
| Gross Profit | $258.34M |
| Operating Income | $75.73M |
| Pretax Income | $75.36M |
| Net Income | $307.19M |
| EBITDA | $79.09M |
| EBIT | $75.73M |
| Reported EPS (TTM) | $3.09 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 84.96% of the $523.88M in total assets.
| Cash and Equivalents | $46.65M |
|---|---|
| Total Debt | $7.24M |
| Net Cash | $39.41M |
| Net Cash Per Share | $2.11 |
| Working Capital | $109.75M |
| Shareholder Equity | $445.11M |
| Book Value Per Share | $23.79 |
| Tangible Book Value | $350.52M |
| Tangible Book Per Share | $18.73 |
| Total Assets | $523.88M |
| Total Liabilities | $78.77M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | $89.92M |
|---|---|
| FCF Per Share | $4.81 |
| Depreciation and Amortization | $4.32M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 26.28%, against a 5-year average of -3.19%.
| Gross Margin | 89.64% |
|---|---|
| Operating Margin | 26.28% |
| Pretax Margin | 26.15% |
| Net Margin | 106.59% |
| EBITDA Margin | 27.44% |
| EBIT Margin | 26.28% |
| Gross Margin (5Y Average) | 94.93% |
| Operating Margin (5Y Average) | -3.19% |
| Net Margin (5Y Average) | 10.46% |
Growth
Revenue grew 34.76% a year over 3 years.
| Revenue Growth (3Y CAGR) | +34.76% |
|---|---|
| Revenue Growth (5Y CAGR) | +22.06% |
Dividends and Yields
RIGL does not pay a dividend.
| Earnings Yield | 7.19% |
|---|---|
| Buyback Yield | -0.33% |
| Shareholder Yield | -0.33% |
Stock Splits
The last split was a 1-for-10 reverse split on Jun 27, 2024.
| Last Split Date | Jun 27, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 7 similar companies, RIGL has the 6th highest P/S.
P/S RatioPeer median 13.1x
ROICPeer median -14.91%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -61.26%
| P/S Ratio | 2.8x vs 13.1x median |
|---|---|
| ROIC | 16.74% vs -14.91% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +2.18% vs -61.26% median |
Analyst Forecast
Consensus estimates put revenue growth at 12.80% and EPS growth at -14.21% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +12.80% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | -14.21% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RIGL
What is RIGL's market cap?
Rigel Pharmaceuticals has a market cap of $823.43M. Its enterprise value, which adds debt and subtracts cash, is $784.02M.
What is RIGL's P/E ratio?
Rigel Pharmaceuticals has a trailing P/E ratio of 13.9x and a forward P/E of 14.5x.
How many shares of RIGL are outstanding?
Rigel Pharmaceuticals has 18.71M shares outstanding. The count is up 3.73% from a year earlier.
Does RIGL pay a dividend?
No. Rigel Pharmaceuticals does not pay a dividend.
How much debt does RIGL have?
Rigel Pharmaceuticals has $7.24M of total debt and $46.65M of cash and equivalents, a net cash position of $39.41M.
RIGL pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors